Living symbiotic bacteria-involved skin dressing to combat indigenous pathogens for microbiome-based biotherapy toward atopic dermatitis

Liu, Xinhua; Qin, Youteng; Dong, Liyun; Han, Zi‐Yi; Liu, Tianning; Tang, Ying; Yu, Yun; Ye, Jing‐Jie; Tao, Juan; Zhang, Xuan; Feng, Jinjun; Zhang, Xian‐Zheng

doi:10.1016/j.bioactmat.2022.08.019

Cited by 12 publications

(4 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further clinical trials are warranted to investigate the long-term efficacy and optimal therapeutic interventions for both R. mucosa and other gram-negative microbial commensal transplantations for AD. Subsequently, a biotherapy has been developed as a live bacterial formulation skin dressing with R. mucosa , hypothesized to colonize and restore the skin microbiome and suppress commensal S. aureus and inflammatory responses [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Bacterial Metabolites and Inflammatory Skin Diseases

Jiminez,

Yusuf

2023

Metabolites

View full text Add to dashboard Cite

The microbiome and gut-skin axis are popular areas of interest in recent years concerning inflammatory skin diseases. While many bacterial species have been associated with commensalism of both the skin and gastrointestinal tract in certain disease states, less is known about specific bacterial metabolites that regulate host pathways and contribute to inflammation. Some of these metabolites include short chain fatty acids, amine, and tryptophan derivatives, and more that when dysregulated, have deleterious effects on cutaneous disease burden. This review aims to summarize the knowledge of wealth surrounding bacterial metabolites of the skin and gut and their role in immune homeostasis in inflammatory skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa.

show abstract

Section: Discussionmentioning

confidence: 99%

Bacterial Metabolites and Inflammatory Skin Diseases

Jiminez,

Yusuf

2023

Metabolites

View full text Add to dashboard Cite

show abstract

“…Topical microbiome transplantation with Roseomonas mucosa for AD patients was associated with significant decreases in measures of disease severity and S. aureus burden (Myles et al, 2018). A Living symbiotic bacteriainvolved skin dressing was developed for microbiome-based biotherapy toward AD, which may recover skin barrier functions and alleviate AD-associated inflammation responses (Liu et al, 2023). Samples for metabolomics analyses can be serum, urine, sweat, skin, etc.…”

Section: Discussionmentioning

confidence: 99%

Multi-omics analyses reveal interactions between the skin microbiota and skin metabolites in atopic dermatitis

Huang,

Li,

Liu

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionAtopic dermatitis (AD) is one of the most common inflammatory skin diseases. Skin microecological imbalance is an important factor in the pathogenesis of AD, but the underlying mechanism of its interaction with humans remains unclear.Methods16S rRNA gene sequencing was conducted to reveal the skin microbiota dynamics. Changes in skin metabolites were tracked by LC–MS metabolomics. We then explored the potential mechanism of interaction by analyzing the correlation between skin bacterial communities and metabolites in corresponding skin-associated samples.ResultsSamples from 18 AD patients and 18 healthy volunteers (HVs) were subjected to 16S rRNA gene sequencing and LC–MS metabolomics. AD patients had dysbiosis of the skin bacterial community with decreased species richness and evenness. The relative abundance of the genus Staphylococcus increased significantly in AD, while the abundances of the genera Propionibacterium and Brevundimonas decreased significantly. The relative abundance of the genera Staphylococcus in healthy females was significantly higher than those in healthy males, while it showed no difference in AD patients with or without lesions. The effects of AD status, sex and the presence or absence of rashes on the number of differentially abundant metabolites per capita were successively reduced. Multiple metabolites involved in purine metabolism and phenylalanine metabolism pathways (such as xanthosine/xanthine and L-phenylalanine/trans-cinnamate) were increased in AD patients. These trends were much more obvious between female AD patients and female HVs. Spearman correlation analysis revealed that the genus Staphylococcus was positively correlated with various compounds involved in phenylalanine metabolism and purine metabolic pathways. The genera Brevundimonas and Lactobacillus were negatively correlated with various compounds involved in purine metabolism, phenylalanine metabolism and sphingolipid signaling pathways.DiscussionWe suggest that purine metabolism and phenylalanine metabolism pathway disorders may play a certain role in the pathogenic mechanism of Staphylococcus aureus in AD. We also found that females are more likely to be colonized by the genus Staphylococcus than males. Differentially abundant metabolites involved in purine metabolism and phenylalanine metabolism pathways were more obvious in female. However, we should notice that the metabolites we detected do not necessarily derived from microbes, they may also origin from the host.

show abstract

“…( C. acnes ) also facilitate S. aureus biofilm formation. A probiotic formulation containing Roseomonas mucosa , poly(vinyl pyrrolidione), poly(vinyl alcohol) and sodium alginate demonstrated antimicrobial activity against S. aureus ( 42 ). Other topical probiotics investigated for skin use include Bacillus , Bifidobacteria , Lactobacillus, Paenibacillus, Pseudomonas, Staphylococcus, Streptococcus , and others ( 43 ).…”

Section: Atopic Dermatitismentioning

confidence: 99%

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists

McAleer

2023

Front. Allergy

View full text Add to dashboard Cite

Atopic dermatitis (AD) is an inflammatory skin disease characterized by epidermal barrier disruption, Th2 immune responses to skin allergens and microbial dysbiosis within affected lesions. Studies within the past decade have revealed genetic and environmental factors contributing to AD in children. Obesity is a metabolic disorder that often manifests early in life and is associated with reduced bacterial diversity, leading to skin colonization with lipophilic bacteria and intestinal colonization with pro-inflammatory species. These changes impair epithelial barriers and promote Th17 responses, which may worsen the severity of AD symptoms. While few studies have examined the contribution of microbiota in obesity-induced allergies, there is emerging evidence that PPAR-γ may be an effective therapeutic target. This review discusses the microbiome in pediatric AD, treatment with probiotics, how disease is altered by obesity and potential therapeutic effects of PPAR-γ agonists. While healthy skin contains diverse species adapted for specific niches, lesional skin is highly colonized with Staphylococcus aureus which perpetuates the inflammatory reaction. Treatments for AD should help to restore microbial diversity in the skin and intestine, as well as epithelial barrier function. Pre-clinical models have shown that PPAR-γ agonists can suppress Th17 responses, IgE production and mast cell function, while improving the epidermal barrier and microbial homeostasis. Overall, PPAR-γ agonists may be effective in a subset of patients with AD, and future studies should distinguish their metabolic and anti-inflammatory effects in order to inform the best therapies.

show abstract

Living symbiotic bacteria-involved skin dressing to combat indigenous pathogens for microbiome-based biotherapy toward atopic dermatitis

Cited by 12 publications

References 61 publications

Bacterial Metabolites and Inflammatory Skin Diseases

Bacterial Metabolites and Inflammatory Skin Diseases

Multi-omics analyses reveal interactions between the skin microbiota and skin metabolites in atopic dermatitis

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists

Contact Info

Product

Resources

About